Pharmaceuticals, Biotechnology and Life Sciences
Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells CAMBRIDGE, England–(BUSINESS WIRE)–Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a…
Alvotech said in a Monday press release it has appointed Joseph Edward McClellan as its new Chief Scientific Officer, who will be leading the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.
– Results Provide First Clinical Demonstration of B7-H4 as a Potential Therapeutic Target and Continue to Support FPA150’s Greatest Potential…
Subgroup exceeds target of 50% improvement in median progression-free survival 12% of patients remain on combination treatment with durations of…
– Results to be presented during a late-breaking oral session at the 2019 ESMO Congress and simultaneously published in The…
– Efficacy of Alecensa in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with…
Novartis will present results from its trial designated Mnaleesa-3, which showed that ribociclib branded as Kisqali has achieved statistically significant improvement in overall survival (OS), which is – according to Novartis – the only CDK4/6 inhibitor to demonstrate positive overall survival in two pivotal Phase III trials — consistently demonstrating approximately 30% reduction in the risk of death.
Elevar Therapeutics presented a study at ESMO, showing the potential of rivoceranib to treat patients with late-stage gastric cancer, which was is the first multinational phase 3 study after rivoceranib’s approval in China, said Dr. Steven Norton, Elevar Therapeutics’ Vice President of Clinical Development.
New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial…
Researchers presented results from Adlai Nortye’s investigational, potentially first in class oral EP4 antagonist, two dose levels of AN0025 in combination with the standard of care for locally advanced rectal cancer where primary resection without chemoradiotherapy is unlikely to achieve clear margins as defined by MRI at ESMO.